The purpose of this study was to evaluate the efficacy and safety of tegoprazan and minocycline dual therapy for Helicobacter pylori initial treatment. It is hypothesized that tegoprazan and minocycline dual therapy is non-inferior to bismuth-containing quadruple therapy.Patients diagnosed with H. pylori infection will be randomly divided into one of the above treatments. At week 6 follow-up visits, a urea breath test#rapid urease test or helicobacter pylori stool antigen test will be performed to confirm eradication.

Start Date01 Sep 2024

Sponsor / Collaborator

Xijing Hospital

ChiCTR2400084473 / RecruitingPhase 4IIT

An Open-label, Single-center, Randomized Controlled Trial Investigating Different Regimens for Eradication of Helicobacter pylori Infection with the Inclusion of Tegoprazan

Start Date20 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Tegoprazan

100 Translational Medicine associated with Tegoprazan

100 Patents (Medical) associated with Tegoprazan

Literatures (Medical) associated with Tegoprazan

01 Dec 2024·JOURNAL OF BIOLOGICAL CHEMISTRY

How ligands modulate the gastric H,K-ATPase activity and its inhibition by tegoprazan

Article

Author: Cerf, Nicole T ; Fedosova, Natalya U ; Rossi, Rolando C ; Filomatori, Claudia V ; Montes, Mónica R ; Faraj, Santiago E ; Zerbetto de Palma, Gerardo

The introduction of potassium-competitive acid blockers (P-CABs) has been a major innovation in gastric H,K-ATPase inhibition and many laboratories are actively engaged in the development of novel molecules within this class. This work investigates the interaction between H,K-ATPase and tegoprazan, a representative of the P-CABs group, in terms of K⁺ and H⁺ binding, through functional and structural analyses. First, by studying the H,K-ATPase activity, we found a model to describe the non-Michaelis-Menten kinetics through a "ping-pong" mechanism that explains a stoichiometry of 1 H⁺, 1 K⁺, and 1 ATP molecule, but also considering the influence of H⁺ on the ionization states of the protein. A kinetic evaluation of the inhibition of tegoprazan denotes the binding to two different intermediates states with apparent K_d (μM) 0.56 ± 0.04 and 2.70 ± 0.24 at pH 7.2. Molecular dynamics simulations revealed important changes in the interactions of tegoprazan with the transmembrane residues depending on whether the site contains K⁺ or not. This explains the decrease in affinity as a function of K⁺ concentration observed in the kinetic experiments. On the other hand, the structures predict that the protonation of tegoprazan is responsible for the change in its dihedral angle. The rotation of the benzimidazole ring allows the inhibitor to be positioned further into the luminal cavity, a situation compatible with the higher inhibition affinity of H,K-ATPase measured at low pH. Results presented herein will provide a basis for the rational design of novel P-CABs ligands.

01 Nov 2024·CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and safety of tegoprazan for duodenal ulcers in Chinese patients: a multicenter, randomized, double-blind, non-inferiority, phase III study

Article

Author: Liao, Aijun ; Chen, Weixing ; Zhang, Shutian ; Wu, Yongdong ; Chen, Honghui ; Hu, Chanyan ; Li, Xing ; Liu, Side ; Zong, Ye ; Lan, Cheng

OBJECTIVE:

Tegoprazan represents a newly developed potassium-competitive acid blocker utilized for the treatment of acid-related disorders. The present study aimed to explore the therapeutic effectiveness of tegoprazan in Chinese individuals with duodenal ulcers (DU).

METHODS:

In the current multicenter, randomized, double-blind, double-dummy, parallel-group, non-inferiority, phase III clinical trial, individuals with DU underwent randomization 1:1 to be administered tegoprazan 50 mg or lansoprazole 30 mg once daily. The primary efficacy endpoint was the 6-week cumulative endoscopic ulcer healing rate. Secondary endpoints included 4-week endoscopic ulcer healing rate and relief of DU-related gastrointestinal symptoms at weeks 2, 4, and 6. Safety analysis encompassed adverse events (AEs) and laboratory indexes.

RESULTS:

The 6-week cumulative endoscopic ulcer healing rates were 96.9% (188/194) and 99.0% (189/191) in the tegoprazan and lansoprazole groups, respectively, indicating a difference of -2.0% (95% confidence interval (CI) = -4.9 to 0.8) in the full analysis set (FAS). The corresponding healing rates were 98.4% (185/188) and 99.5% (183/184) in the per-protocol set, respectively, indicating a difference of -1.1% (95% CI = -3.1 to 1.0). The 4-week healing rates in the tegoprazan and lansoprazole groups were 89.2% (173/194) and 88.5% (169/191) in the FAS, respectively, with a difference of 0.7% (95% CI = -5.6 to 7.0). Treatment-related AEs, all mild-to-moderate, were reported in 38.2% (78/204) and 48.2% (94/195) of participants in the tegoprazan and lansoprazole groups, respectively.

CONCLUSIONS:

Tegoprazan 50 mg once daily is effective and non-inferior to lansoprazole 30 mg once daily in Chinese patients with DU, showing a promising safety and tolerability profile.

CLINICALTRIALS.GOV REGISTRATION NUMBER:

NCT05010954.

01 Nov 2024·Current gastroenterology reports

Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

Review

Author: Scarpignato, Carmelo ; Hunt, Richard H

Abstract:

Purpose of the Review:

Acid suppression with proton pump inhibitors (PPIs) represents the standard of care in the treatment of acid-related diseases. However, despite their effectiveness, PPIs display some intrinsic limitations, which underlie the unmet clinical needs that have been identified over the past decades. The aims of this review are to summarize the current status and future development of the new class of antisecretory drugs (potassium-competitive acid blockers, P-CABs) that have recently been introduced into medical practice.

Recent Findings:

Over the past decades, clinical needs unmet by the current acid suppressants have been recognized, especially in the management of patients with GERD, Helicobacter pylori infection and NSAID-related peptic ulcer. The failure to address these needs is mainly due to their inability to achieve a consistent acid suppression in all patients and, particularly, to control nighttime acidity. It was then realized that an extended duration of acid suppression would exert additional benefits. The available data with P-CABs show that they are able to address these unmet clinical needs.

Summary:

Four different P-CABs (vonoprazan, tegoprazan, fexuprazan and keverprazan) are currently available. However, only two of them are approved outside Asia. Vonoprazan is available in North, Central and South America while tegoprazan is marketed only in Latin American countries. Two other compounds (namely linazapran glurate and zestaprazan) are presently under clinical development. While clinical trials on GERD have been performed with all P-CABs, only vonoprazan and tegoprazan have been investigated as components of Helicobacter pylori eradication regimens. The available data show that—in the above two clinical indications—P-CABs provide similar or better efficacy in comparison with PPIs. Their safety in the short-term overlaps that of PPIs, but data from long-term treatment are needed.

News (Medical) associated with Tegoprazan

26 Sep 2024

·www.inno-n.com

K-CAB, HK inno.N’s new GERD treatment approved in Malaysia

September 26, 2024 K-CAB, HK inno.N’s new GERD treatment approved in Malaysia K-CAB obtains marketing authorization in Malaysia following the recent of news of MA in 6 Latin American countries...Ongoing achievements of MA and product release of K-CAB in the global market K-CAB succeeded in the global market entry across 46 countries including South Korea, and product launch in 9 countries...Expansion of K-CAB’s global market presence continues K-CAB, HK inno.N's novel drug for Gastroesophageal Reflux Disease (GERD) treatment, obtained marketing authorization in Malaysia. HK inno.N announced on September 26 that K-CAB (tegoprazan) obtained marketing authorization (MA) from National Pharmaceutical Regulatory Agency (NPRA) of Malaysia. The MA follows an agreement signed in 2021 with No. 1 Malaysian pharmaceutical company, Pharmaniaga Logistic Sdn Bhd, for the export of K-CAB drug products. K-CAB is approved for the four indications: △ treatment of Erosive Gastroesophageal Reflux Disease △ treatment of Non-Erosive Gastroesophageal Reflux Disease △ treatment of Gastric Ulcer △ Antibiotic combination therapy for eradication of Helicobacter pylori in patients with peptic ulcers and/or chronic atrophic gastritis. K-CAB will be marketed under the same local product name of ‘K-CAB,’ and preparation is underway for its product launch in Malaysia in the first half of 2025. K-CAB’s entry to global pharmaceutical markets spans across 45 countries including the US and China, of which nine countries including South Korea had official product launches. In Southeast Asia, K-CAB entered the six largest economies in the region, which includes ▲Philippines ▲Indonesia ▲Singapore. The Southeast Asian market for peptic ulcer medications is estimated at approximately $520 million, with rising anticipation for its growth potential. “K-CAB’s market entry to major countries in Southeast Asia will provide yet another momentum for its growing market presence,” commented Dalwon Kwak, CEO of HK inno.N. “Beyond Southeast Asia, we aim to establish K-CAB as a leading product of the P-CAB class drugs in the global market, raising the profile of drugs developed in South Korea.” K-CAB, the 30th new drug in South Korea, is a P-CAB class new drug for GERD treatment. It is characterized by rapid onset of action within one hour after administration and proven efficacy and safety even with long-term use for up to six months. Since its domestic launch in 2019, K-CAB recorded a total outpatient prescription sales of KRW 761.1 billion to August 2024. The product has been the steady No. 1 market leader in peptic ulcer medications for four consecutive years since its launch. [The End] [Reference information] ■ P-CAB: Potassium Competitive Acid Blocker. ■ K-CAB is launched in the following countries (9 countries/market entry to a total of 46 countries) - South Korea, China, Mongolia, Philippines, Mexico, Indonesia, Singapore, Peru, Chile ■ K-CAB’s successful track record of market entry to Southeast Asia includes the following 6 countries: Indonesia, Thailand, Philippines, Singapore, Vietnam, Malaysia ■ Overview of K-CAB’s market presence in Southeast Asia - Product release (3 countries): Philippines(Nov 2022), Indonesia(Jul 2023), Singapore(Aug 2023) - Marketing authorization (2 countries): Malaysia, Thailand - Marketing authorization under review: Vietnam ■ Estimation of the peptic ulcer drugs market size in Southeast Asia (for 2023): 526,800,000$ (Source: IQIVA ※ Based on the seven countries in the region: Indonesia, Vietnam, Thailand, Philippines, Singapore, Malaysia, Sri Lanka)

Drug ApprovalLicense out/in

27 Jun 2024

·www.inno-n.com

HK inno.N launches K-CAB ODT 25mg for treatment of GERD

June 27, 2024 HK inno.N launches K-CAB ODT 25mg for treatment of GERD Designed to be rapidly dissolved in the mouth without the need for swallowing … To be released on the 1st of July Releasing 25mg (low-dose) following the launch of the existing product, K-CAB ODT 50mg… Development ongoing for ensuring availability in diverse formulations and doses The only product with ODT formulation and indication for maintenance therapy among P-CAB class products released in Korea HK inno.N announced on 27th that the low-dose form (25mg) of the company’s blockbuster drug K-CAB (tegoprazan) ODT for treatment of gastroesophageal reflux disease (GERD) will be launched as of 1st of July. As with K-CAB Tablet 25 mg, the new product is indicated for “maintenance therapy after treatment of erosive GERD.” K-CAB is the only product available in the formulation of orally disintegrating tablet (ODT) among the P-CAB class products released in Korea. K-CAB ODT rapidly dissolves in the mouth, which provides a patient-friendly option for those having difficulty swallowing tablets or drinking water or patients of advanced age. HK inno.N released K-CAB ODT 50mg in May 2022, and its half-dose formulation, K-CAB ODT 25mg will be released next month. Following the new product launch, the K-CAB product series is now available in four different types to meet diverse needs of the patients: ▲ K-CAB Tablet 25mg ▲ K-CAB Tablet 50mg ▲ K-CAB ODT 25mg ▲ K-CAB ODT 50mg. The cumulative outpatient prescription sales of K-CAB series in the last year alone recorded KRW 158.2 billion, continuing to cement its position as the No. 1 market leader in peptic ulcer drugs in Korea. Among the products, K-CAB ODT 50mg, released in 2022, recorded the outpatient prescription sales at KRW 25.1 billion for the last year, making its mark in the ongoing trend of rapid growth of K-CAB series. It is expected that the launch of the new low-dose ODT product will further contribute to the sales growth and market share expansion of K-CAB series. An official from HK inno.N commented, “Through continuous R&D, the available formulations and dose options of K-CAB have diversified, as well as expanding its indications, which contributes to boosting patient compliance and providing a wider range of therapeutic options for the patients,” and added, “Our multifaceted efforts will continue to solidify K-CAB series’ market leading position for peptic ulcer drugs in Korea, and provide added values to new drugs manufactured in Korea. K-CAB, the 30th new drug in South Korea, provides a next-generation option for treatment of GERD, overcoming limitations of the existing therapeutic agents. Since its release in 2019, K-CAB has been the steady No. 1 market leader in peptic ulcer medications for four consecutive years. The drug’s cumulative outpatient prescription sales up to May 2024 has reached KRW 585.3 billion. K-CAB is approved for five indications, boasting the most diverse range of indications among P-CAB class products released in Korea. It is characterized by rapid onset of action within one hour after administration, suppression of night-time gastric acid secretion, and boosting patient compliance with its simplified regimen irrespective of meal times. The diverse dose and formulation options of K-CAB allows the drug to be used across a range of stages from treatment of GERD to maintenance therapy. [The end] [Reference Information] ■ P-CAB: Potassium Competitive Acid Blocker ■ Indications of K-CAB 1) Erosive Gastroesophageal Reflux Disease 2) Non-Erosive Gastroesophageal Reflux Disease 3) Gastric Ulcer 4) Antibiotic combination therapy for eradication of Helicobacter pylori in patients with peptic ulcers and/or chronic atrophic gastritis. 5) Maintenance therapy after treatment of erosive Gastroesophageal Reflux Disease (For 25mg product only) June 27, 2024 HK inno.N launches K-CAB ODT 25mg for treatment of GERD Designed to be rapidly dissolved in the mouth without the need for swallowing … To be released on the 1st of July Releasing 25mg (low-dose) following the launch of the existing product, K-CAB ODT 50mg… Development ongoing for ensuring availability in diverse formulations and doses The only product with ODT formulation and indication for maintenance therapy among P-CAB class products released in Korea Designed to be rapidly dissolved in the mouth without the need for swallowing … To be released on the 1st of July Releasing 25mg (low-dose) following the launch of the existing product, K-CAB ODT 50mg… Development ongoing for ensuring availability in diverse formulations and doses The only product with ODT formulation and indication for maintenance therapy among P-CAB class products released in Korea HK inno.N announced on 27th that the low-dose form (25mg) of the company’s blockbuster drug K-CAB (tegoprazan) ODT for treatment of gastroesophageal reflux disease (GERD) will be launched as of 1st of July. As with K-CAB Tablet 25 mg, the new product is indicated for “maintenance therapy after treatment of erosive GERD.” K-CAB is the only product available in the formulation of orally disintegrating tablet (ODT) among the P-CAB class products released in Korea. K-CAB ODT rapidly dissolves in the mouth, which provides a patient-friendly option for those having difficulty swallowing tablets or drinking water or patients of advanced age. HK inno.N released K-CAB ODT 50mg in May 2022, and its half-dose formulation, K-CAB ODT 25mg will be released next month. Following the new product launch, the K-CAB product series is now available in four different types to meet diverse needs of the patients: ▲ K-CAB Tablet 25mg ▲ K-CAB Tablet 50mg ▲ K-CAB ODT 25mg ▲ K-CAB ODT 50mg. The cumulative outpatient prescription sales of K-CAB series in the last year alone recorded KRW 158.2 billion, continuing to cement its position as the No. 1 market leader in peptic ulcer drugs in Korea. Among the products, K-CAB ODT 50mg, released in 2022, recorded the outpatient prescription sales at KRW 25.1 billion for the last year, making its mark in the ongoing trend of rapid growth of K-CAB series. It is expected that the launch of the new low-dose ODT product will further contribute to the sales growth and market share expansion of K-CAB series. An official from HK inno.N commented, “Through continuous R&D, the available formulations and dose options of K-CAB have diversified, as well as expanding its indications, which contributes to boosting patient compliance and providing a wider range of therapeutic options for the patients,” and added, “Our multifaceted efforts will continue to solidify K-CAB series’ market leading position for peptic ulcer drugs in Korea, and provide added values to new drugs manufactured in Korea. K-CAB, the 30th new drug in South Korea, provides a next-generation option for treatment of GERD, overcoming limitations of the existing therapeutic agents. Since its release in 2019, K-CAB has been the steady No. 1 market leader in peptic ulcer medications for four consecutive years. The drug’s cumulative outpatient prescription sales up to May 2024 has reached KRW 585.3 billion. K-CAB is approved for five indications, boasting the most diverse range of indications among P-CAB class products released in Korea. It is characterized by rapid onset of action within one hour after administration, suppression of night-time gastric acid secretion, and boosting patient compliance with its simplified regimen irrespective of meal times. The diverse dose and formulation options of K-CAB allows the drug to be used across a range of stages from treatment of GERD to maintenance therapy. [The end] [Reference Information] ■ P-CAB: Potassium Competitive Acid Blocker ■ Indications of K-CAB 1) Erosive Gastroesophageal Reflux Disease 2) Non-Erosive Gastroesophageal Reflux Disease 3) Gastric Ulcer 4) Antibiotic combination therapy for eradication of Helicobacter pylori in patients with peptic ulcers and/or chronic atrophic gastritis. 5) Maintenance therapy after treatment of erosive Gastroesophageal Reflux Disease (For 25mg product only) inno.N Minjoo KangManager(Communication team) E-Mail minjoo.kang0@inno-n.com Address 6~8F, A-dong, 100, Eulji-ro, Jung-gu, Seoul inno.N Minjoo KangManager(Communication team) E-Mail minjoo.kang0@inno-n.com Address 6~8F, A-dong, 100, Eulji-ro, Jung-gu, Seoul

Drug Approval

08 May 2024

·www.echemi.com

Breaking News: $56 Million Investment as GLP-1 Makes Its Way to South Korea

In a groundbreaking development, the biopharmaceutical company Sciwind Biosciences has announced a strategic partnership with HKinno.N Corporation, a leading pharmaceutical company in South Korea. The partnership involves the licensing and commercialization of Ecnoglutide Injection (XW003), a novel GLP-1 agonist, in the South Korean market. This collaboration marks a significant milestone in the expansion of GLP-1 therapies and is projected to be a game-changer in treating type 2 diabetes, obesity, and metabolic disorders such as non-alcoholic steatohepatitis (NASH). Partnership Details: According to the agreement, Sciwind Biosciences will receive an upfront payment and become eligible for milestone payments of up to $56 million for research, development, registration, and commercialization of Ecnoglutide Injection. Additionally, the company will receive a substantial royalty based on the product's sales in South Korea. HKinno.N Corporation, on the other hand, gains exclusive rights for the development and commercialization of Ecnoglutide Injection within the South Korean market. However, Sciwind Biosciences retains the rights to develop and commercialize the product in all other global markets. The Powerhouse Partnership: HKinno.N Corporation, formerly the pharmaceutical division of CJ CheilJedang Corp, has a rich history in the pharmaceutical industry. With over 16,000 international patents and more than 20,000 product formulations in skincare and medicine, the company boasts an impressive clientele and is considered a leading player in the consumer healthcare sector in South Korea. Leveraging their experience in successfully developing and commercializing K-CAB, a novel gastroesophageal reflux disease medication, HKinno.N Corporation aims to position Ecnoglutide Injection as a blockbuster drug with sales exceeding 100 billion Korean won in the South Korean market. The Potential of Ecnoglutide Injection: Ecnoglutide Injection is a newly developed GLP-1 agonist with a unique cyclic adenosine monophosphate (cAMP) bias. It demonstrates potential in treating type 2 diabetes, obesity, and metabolic disorders such as NASH. GLP-1 agonists have shown efficacy in managing type 2 diabetes and obesity by promoting insulin secretion and reducing appetite, with minimal risk of hypoglycemia. Ecnoglutide Injection, optimized for enhanced biological activity and cost-effectiveness, offers the convenience of once-weekly dosing. Clinical trials have shown promising results, with significant reductions in glycated hemoglobin (HbA1c) and body weight observed in patients. Future Prospects and Market Demand: Metabolic diseases affect millions of patients in South Korea, making the introduction of Ecnoglutide Injection a vital development. Dalwon Kwak, CEO of HKinno.N Corporation, expressed confidence in the product's clinical profile and differentiated features. Sciwind Biosciences's collaboration will accelerate the drug's research and development in the South Korean market. The demand for diabetes and weight management drugs is substantial, and GLP-1 receptor agonists have gained popularity due to their favorable effects on insulin secretion and appetite control, coupled with a low risk of side effects. Sciwind Biosciences, with its pioneering approach, has established a strong presence in this market. The strategic partnership between Sciwind Biosciences and HKinno.N Corporation brings the promising GLP-1 agonist, Ecnoglutide Injection, to the South Korean market. This alliance not only signifies a major investment of $56 million but also heralds a new era in the treatment of type 2 diabetes, obesity, and metabolic disorders. With the potential to revolutionize the healthcare landscape, Ecnoglutide Injection holds great promise for improving the lives of patients in South Korea and beyond.

License out/in

100 Deals associated with Tegoprazan

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	A02BC	DB16690

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Duodenal Ulcer	CN	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	14 Nov 2023
Esophagitis, Peptic	CN	Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.	08 Apr 2022
Gastroesophageal Reflux	KR	HK inno.N Corp.	05 Jul 2018
Helicobacter pylori infection	KR	HK inno.N Corp.	05 Jul 2018

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stomach Ulcer	Phase 3	KR	HK inno.N Corp.	01 May 2016
Non-erosive gastro-esophageal reflux disease	Phase 3	KR	HK inno.N Corp.	22 Sep 2015
Non-erosive reflux disease	Phase 3	KR	HK inno.N Corp.	22 Sep 2015
Erosive esophagitis	Phase 3	KR	HK inno.N Corp.	01 May 2015
Liver Injury	Phase 1	KR	HK inno.N Corp.	08 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2024	Not Applicable	Helicobacter pylori infection First line	80	Tegoprazan-based BQT	nltaaftsei(ippitjurpk) = There was no significant difference in the rate of adverse events between the TBMT and OBMT groups (42.5% vs. 55,5%, p = 0.37). Nausea was the most common adverse effect (37.5% vs 40%, p=0.92) , followed by abdominal pain (12.5% vs 17.5%, p=0.16%) ogjtqtjaqb (bhyofkotwm )	Positive	13 Oct 2024
				Omeprazole-based BQT
UEGW	Not Applicable	-	-	Esomeprazole-containing sequential therapy	kqokxpgisx(ivdozgwgzv) = In tegoprazan-containing sequential, nausea was more prevalent (23.3%, 27/202), which was statistically higher than esomeprazole-containing sequential (14.2%, 29/204) (p = 0.022) eivjypietx (hsthlodkxd )	-	13 Oct 2024
				Tegoprazan-containing sequential therapy
UEGW	Not Applicable	-	-	Tegoprazan 50mg	nmedvbbeyn(mthqcrovpz) = No significant differences in the incidence of adverse events between the trial group and the placebo group. No severe adverse events occurred in this study. vcavbzxgva (lfadcqexlv )	-	13 Oct 2024
				Placebo
NCT05010954 (Pubmed \| Curr Med Res Opin) Manual	Phase 3	Duodenal Ulcer	399	Tegoprazan 50 mg	vzecrngrxj(rftwxgzlwg) = rviarzbvgq abgnzpncml (lvkvsdllaw ) View more	Non-inferior	08 Oct 2024
				Lansoprazole 30 mg	vzecrngrxj(rftwxgzlwg) = rneuzhpuci abgnzpncml (lvkvsdllaw ) View more
NCT06382493 (Pubmed \| Helicobacter)	Not Applicable	Helicobacter pylori infection	406	Esomeprazole-containing sequential therapy	izpcuuhbch(vdyiortyva) = Nausea was more prevalent (23.3%, 27/202) with sequential tegoprazans than with esomeprazole-containing sequential therapy (14.2%, 29/204; p = 0.022) bbhnwwbblj (gswmmxbtez )	Positive	01 Sep 2024
				Tegoprazan-containing sequential therapy
NEWS Manual	Phase 3	Helicobacter pylori infection	555	替戈拉生	cczpttylsh(hzxlcobrys) = wmogpixagt hzgtmqphum (lsrqxvphwp ) View more	Positive	21 May 2024
				艾司奥美拉唑	cczpttylsh(hzxlcobrys) = swgtkzjjjd hzgtmqphum (lsrqxvphwp ) View more
DDW2024	Not Applicable	-	612	Tegoprazan	qffyupoqai(nszlfijjrv) = aasfnzovag gkpvtyivqo (hmwacrrhcy ) View more	Positive	21 May 2024
				PPI	qffyupoqai(nszlfijjrv) = jldsxgpojj gkpvtyivqo (hmwacrrhcy ) View more
NCT05870683 (SHARE2301, Pubmed)	Not Applicable	Helicobacter pylori infection	368	Tegoprazan-amoxicillin (TA)	wtpujotlsx(nqgvhuikmc) = ztfsicwlyy tptcnejcck (ivpbtcbsei )	Positive	01 May 2024
				Esomeprazole-amoxicillin (EA)	wtpujotlsx(nqgvhuikmc) = mluivgvtah tptcnejcck (ivpbtcbsei )
NCT04022096 (Pubmed) Manual	Phase 3	Erosive esophagitis	351	Tegoprazan	ywdsikcpmp(irslpfckoe) = iihyronpdj uqfrdnofte (mvacvixkwz )	Non-inferior	31 Oct 2022
				lansoprazole	ywdsikcpmp(irslpfckoe) = pwhibnglpn uqfrdnofte (mvacvixkwz )
NCT03317223 (Pubmed) Manual	Phase 3	Helicobacter pylori infection First line	350	amoxicillin+clarithromycin+tegoprazan	uxcfbcntiw(xdefyzojjl) = upwatxbstd dgbfxaqtbo (viguepawgl ) View more	Non-inferior	06 Jul 2022
				amoxicillin+clarithromycin+lansoprazole	uxcfbcntiw(xdefyzojjl) = jpnfleqgmw dgbfxaqtbo (viguepawgl ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis